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Objectives: Inhaled nitric oxide is a promising therapy to control pulmonary 
hypertension. However, pulmonary hypertension caused by valvular heart 
disease is often refractory to inhaled nitric oxide. The objective of this study 
was to determine whether the combination of inhaled nitric oxide plus 
dipyridamole will cause a response in patients with pulmonary hypertension 
undergoing cardiac operations who had not responded to inhaled nitric oxide 
alone. Methods: Responses in 10 patients (62 - 7 years) with pulmonary 
hypertension caused by aortic or mitral valvular disease (mean pulmonary 
artery pressure, _>30 mm Hg) were studied in the operating room after valve 
replacement. The effect of inhaled nitric oxide alone (40 ppm) on pulmonary 
vascular esistance, mean pulmonary artery pressure, cardiac output, and 
mean arterial pressure was determined. Inhaled nitric oxide administration 
was then stopped and patients were given dipyridamole (0.2 mg/kg intrave- 
nously); the effect of inhaled nitric oxide plus dipyridamole was then examined. 
Results: Dipyridamole effected a response in patients who had not responded to
nitric oxide. Pulmonary vascular resistance and mean pulmonary artery 
pressure were significantly reduced and cardiac output was increased without 
change in mean arterial pressure. Conclusions: Patients with refractory pul- 
monary hypertension i  whom inhaled nitric oxide alone fails to cause a 
response may respond to combined therapy of inhaled nitric oxide plus 
dipyridamole. This therapy may be particularly valuable in patients with 
dysfunction of the right side of the heart as a result of pulmonary hypertension 
because of its effective lowering of right ventricular afterload. (J Thorac 
Cardiovasc Surg 1997;113:363-70) 
I ncreased pulmonary vascular resistance (PVR) may greatly complicate the perioperative treat- 
ment of patients undergoing cardiac operations. 
Because PVR is the primary clinical determinant of 
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right ventricular afterload, increased PVR may re- 
sult in right ventricular afterload mismatch, compro- 
mising cardiac output. Pharmacologic agents that 
are currently used as pulmonary vasodilators typi- 
cally produce vasodilation of both the systemic and 
pulmonary circulations. Such nonselective vasodila- 
tion may be hazardous in patients with increased 
PVR1; significant hypotension may result if the 
degree of systemic vasodilation exceeds that of the 
pulmonary vasodilation. 
Inhaled nitric oxide (NO) is a promising therapy 
to control pulmonary hypertension. 2 It has been 
shown to produce a significant reduction in both 
pulmonary arterial pressure and PVR without re- 
ducing systemic arterial pressure or systemic vascu- 
lar resistance in patients after cardiac operation. It 
may therefore be clinically valuable as a "selective" 
pulmonary vasodilator in patients undergoing car- 
363 
3 6 4 Fullerton et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
February 1997 
diac operation. 3 Mechanistically, inhaled NO lowers 
PVR by stimulating uanylate cyclase in pulmonary 
vascular smooth muscle to produce guanosine 3',5'- 
cyclic guanosine monophosphate (cGMP), which in 
turn produces vascular smooth muscle relaxation by 
mechanisms that are yet unclear. 4 The net concen- 
tration of cGMP within pulmonary vascular smooth 
muscle is determined by the balance of its produc- 
tion by guanylate cyclase and degradation by phos- 
phodiesterase. 
In patients undergoing cardiac operations who 
have pulmonary hypertension, the hypertension fre- 
quently is a result of valvular heart disease. Valvular 
heart disease produces remodeling of the pulmo- 
nary vascular bed, which in turn may reduce the 
effectiveness of NO in lowering PVR. 2 In patients in 
whom pulmonary hypertension does not respond to 
inhaled NO, we hypothesized that the effectiveness 
of inhaled NO could be increased with the use of a 
two-pronged approach: (1) stimulating cGMP pro- 
duction with inhaled NO and (2) preventing the 
breakdown of cGMP by inhibiting the enzyme re- 
sponsible for its degradation, phosphodiesterase. 
The purpose of this study was to determine whether 
the combination of stimulating cGMP production 
(inhaled NO) plus preventing cGMP breakdown by 
phosphodiesterase inhibition (dipyridamole) will 
cause a response in patients with pulmonary hyper- 
tension undergoing cardiac operation in whom in- 
haled NO alone had failed to cause a response. 
The results of this study demonstrate that this 
two-pronged approach may be an effective strategy 
to control pulmonary hypertension i patients un- 
dergoing cardiac operations. 
Methods 
This protocol was approved by the Human Subjects 
Review Committee of the University of Colorado Health 
Sciences Center and the Research and Development 
Committee, Human Subjects Subcommittee of the Den- 
ver Veterans Affairs Medical Center. Informed consent 
was obtained from each participant. 
Administration of inhaled NO. Inhaled NO was sup- 
plied in tanks of 2200 ppm (Scott Medical Products, 
Plumsteadville, Pa.) and was administered into the in- 
spiratory arm of the anesthesia breathing circuit. The 
concentration f inhaled NO was continuously monitored 
at a location just proximal to the endotracheal tube by 
chemoluminescence (chemoluminescence monitor model 
42H, Thermo Environmental Instruments Inc., Franklin, 
Mass.). The exhalation limb of the breathing circuit was 
likewise continuously monitored by chemoluminescence 
for NO a and NOx (toxic higher oxides of NO). 
Protocol for data collection. Ten patients (62 _+ 7 
years) with pulmonary hypertension caused by aortic or 
mitral valvular disease (mean pulmonary artery pressure 
->30 mm Hg) underwent s udy in the operating room after 
valve replacement. Patients received preoperative medi- 
cation consisting of morphine sulfate 0.1 mg/kg and 
scopolamine 0.4 mg intramuscularly 1 hour before arrival 
in the operating room. Ongoing drug therapy for concom- 
itant medical problems was continued as deemed appro- 
priate by the attending anesthesiologist. 
Monitoring in each patient was done with a five-lead 
electrocardiogram, a radial arterial line, and a pulmonary 
artery thermodilution ximetric atheter (Abbot Labora- 
tories, Chicago, Ill.) introduced through the right internal 
jugular vein. To accurately measure pulmonary venous 
outflow pressure (left atrial pressure) for determination f 
PVR, a left atrial pressure monitoring catheter was intro- 
duced into the left atrium via the right superior pulmonary 
vein after the patient had been weaned from cardiopul- 
monary bypass. The left atrial pressure catheter was 
subsequently removed after completion of data collection 
and before chest closure. The anesthetic technique con- 
sisted of a high-dose narcotic (fentanyl) and relaxant 
(vecuronium) technique supplemented with intravenous 
midazolam. Inhalational anesthetic agents were adminis- 
tered only during cardiopulmonary b pass. 
Data were collected in the operating room beginning 
approximately 20minutes after completion of cardiopul- 
monary bypass but before chest closure. After weaning 
from bypass and after protamine administration, all pa- 
tients were in hemodynamically stable condition and 
demonstrated normal coagulation. No patients required 
cardiac pacing, antiarrhythmic therapy, or inotropic or 
vasoactive drug administration. No inhalational nesthet- 
ics were administered after the time of cessation of 
cardiopulmonary b pass or during the period of data 
collection. 
The protocol for collection of data proceeded as fol- 
lows: tidal volume was set at approximately 10ml/kg and 
respiratory rate adjusted to establish an arterial carbon 
dioxide tension (Pco2) of approximately 40mm Hg and an 
arterial pH of approximately 7.40. 5To avoid changes in 
pulmonary hemodynamics aused by changes in ventila- 
tory patterns, ventilator settings were subsequently not 
altered during the study period. Fraction of inspired 
oxygen was maintained at a mean of 0.97 (range 0.94 to 
0.99) and no patient had the application of positive 
end-expiratory pressure at any point during the study 
period. Arterial oxygen tension (Po2) was therefore main- 
tained at greater than 250 mm Hg throughout the study 
period to avoid any influence of hypoxemia on pulmonary 
vascular tone. Arterial and mixed venous blood gas sam- 
ples were obtained at each point of data collection. The 
hemodynamic variables measured and recorded were 
heart rate, systemic mean arterial blood pressure, mean 
pulmonary arterial pressure, central venous pressure, left 
atrial pressure, and thermodilution cardiac output (mean 
of three values). These allowed mathematical derivation 
of pulmonary and systemic vascular esistance, cardiac 
index, right ventricular stroke work index, and transpul- 
monary gradient. 
After placement of the left atrial pressure line and with 
the patient in a hemodynamic steady-state condition, 
baseline hemodynamic variables were determined. Then 
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40 ppm of NO was added to the ventilatory circuit. After 
10 minutes of administration of inhaled NO, 40 ppm, 
hemodynamic variables were determined. The inhaled 
NO administration was then stopped, and hemodynamic 
variables determined. Dipyridamole (Boehringer, Rich- 
field, Conn.) (0.2 mg/kg intravenously) was then slowly 
administered. After measurement of hemodynamic vari- 
ables, 40 ppm of NO was again added to the ventilatory 
circuit. After 10 minutes, hemodynamic variables were 
measured anLd inhaled NO administration was then 
stopped. After 10 minutes, hemodynamic data after ad- 
ministration of inhaled NO were collected. The left atrial 
pressure line 'was then removed under direct vision and its 
insertion site in the right superior pulmonary vein was 
determined to be hemostatic. Methemoglobin level was 
determined before and after data collection. 
Statistical analysis. Statistical analyses were done with 
a Macintosh Quadra 650 computer (Apple Computer, 
Inc., Cupertino, Calif.) and StatView software (Brain 
Power, Inc., Calabasas, Calif.). Data are presented as 
mean plus or minus 1 standard error of the mean. 
Statistical evaluation used standard analysis of variance in 
conjunction with the Student-Newman-Keuls multiple 
comparisons procedure. At p value of less than 0.05 was 
accepted as statistically significant. 
Results 
The study population comprised 10 patients, and 
subject demographics are listed in Table I. All 
patients had a history of cigarette smoking; however, 
none demonstrated clinical or radiographic evi- 
dence of significant chronic pulmonary disease. 
Table II lists the arterial and mixed venous blood 
gas values along with the hemodynamic variables 
determined at each point of data collection. There 
were no changes in values of arterial pH, arterial 
Po2, or arterial Pco 2 throughout the study period. 
Likewise there were no significant changes in heart 
rate, central venous pressure, or left atrial pressure 
throughout the period of data collection. Methemo- 
globin concentration was 2.1 _+ 0.1 before NO 
administration a d was unchanged after inhaled NO 
administration. 
No hemodynamic effects were noted with either 
inhaled NO, alone or dipyridamole alone (Table II). 
However, the combination of inhaled NO and dipy- 
ridamole produced a significant reduction in 
transpulmonary gradient (Table II) and mean pul- 
monary artery pressure without a change in mean 
systemic arterial pressure (Fig. 1). This reduction in 
pulmonary arterial pressure resulted in a significant 
increase in cardiac output (Table II) and a signifi- 
cant reduction in PVR (Fig. 2). The calculated 
systemic vascular esistance also was lower because 
cardiac output increased without a change in mean 
systemic arterial pressure (Table II). However, be- 
Table I. Patient demographics 
No. of patients 10 
Age (yr) 62 +_ 7 
Aortic crossclamp time (min) 96 ± 13 
Cardiopulmonary b pass time (min) 129 ± 16 
Tidal volume (cc/kg) 10 
Respiratory rate (breaths/min) 11 
Values are mean plus or minus the standard error of the mean. 
cause the ratio of pulmonary-to-systemic vascular 
resistance fell, it would appear that.the vasodilating 
action of inhaled NO plus dipyridamole is preferen- 
tial to the pulmonary circulation (Table II). 
Discussion 
The results of this study demonstrate that a 
two-pronged approach of stimulating cGMP pro- 
duction with inhaled NO and preventing the break- 
down of cGMP by inhibiting the enzyme responsible 
for its degradation, phosphodiesterase, effects a 
response in patients with pulmonary hypertension 
undergoing cardiac operation in whom inhaled NO 
alone had failed to cause a response. 
As in the present study, most adult patients 
undergoing cardiac operation who have pulmonary 
hypertension have this pulmonary hypertension as~i 
result of mitral or aortic valvular disease. At  least 
three pathophysiologic mechanisms contribute to 
the pulmonary hypertension seen in long-standing 
aortic or mitral valvular disease: (1) increased left 
atrial pressure transmitted on a retrograde basis into 
the arterial circulation, (2) vascular emodeling of 
the pulmonary vasculature in response to chronic 
obstruction to pulmonary venous drainage ("fixed 
component"), and (3) pulmonary arterial vasocon- 
striction ("reactive component"). 6 Once the ele- 
vated left atrial pressure is relieved by valve replace- 
ment, the increased PVR does not immediately 
return to the normal range; several days to weeks 
may be required. The pulmonary vasoconstrictive 
effects of cardiopulmonary b pass are well recog- 
nized, and patients with chronic pulmonary vascular 
structural changes may have an exaggerated re- 
sponse to vasoconstricting a onists. The results of 
the present study suggest hat the "reactive" com- 
ponent of the increased PVR in such patients may 
be modulated with a combination therapy thatin-  
creases cGMP production (inhaled NO) and pre- 
vents cGMP breakdown (dipyridamole). 
Patients undergoing cardiac operation provided a 
unique opportunity to examine the influence of 
inhaled NO on PVR. A homogeneous group of 
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Table II. Hemodynamic data 
Before NO a lone Dipyridamole a one NO plus dipyridamole After 
Temperature (°C) 36.2 ± 0.5 36.2 ± 0.5 36.2 _+ 0.5 36.0 +_ 0.5 36.0 ± 0.5 
Hemoglobin (gm/dl) 8.7 _+ 0.5 8.7 _+ 0.5 8.4 -- 0.5 8.5 ± 0.5 8.3 __- 0.5 
Arterial pH 7.44 _+ 0.03 7.41 ± 0.03 7.43 + 0.03 7.46 _+ 0.03 7.42 -+ 0.03 
Arterial Po2 (mm Hg) 276 ± 37 265 ± 29 297 _+ 35 278 -+ 21 264 ± 33 
Arterial Pco2 (mm Hg) 35 - 3 38 _+ 3 32 _+ 3 33 ± 3 33 ± 3 
Venous pH 7.33 _+ 0.01 7.32 ± 0.01 7.31 _+ 0.01 7.37 ± 0.01 7.33 ± 0.01 
Venous Po2 (mm Hg) 37 ± 2 36 ± 2 36 -+ 2 39 ± 2 35 ± 2 
Venous Pc% (mm Hg) 45 ± 4 46 ± 4 46 _+ 4 44 ± 4 45 _+ 4 
Heart rate (rain -1) 96 _+ 7 94 _+ 7 98 ± 6 95 _+ 4 95 + 9 
CVP (mm Hg) 9 + 2 10 ± 3 10 _+ 3 10 ± 2 9 + 1 
LAP (mm Hg) 11 ± 2 11 ± 2 10 ± 2 10 _+ 2 9 ± 2 
MPAP (ram Hg) 39 ± 3 40 _+ 4 39 + 3 29 ± 3* 38 ± 3 
TPG (mm Hg) 28 ± 3 29 _+ 3 29 _+ 3 19 ± 3* 27 _+ 3 
Cardiac output (L/min) 3.6 - 0.4 3.5 ± 0.4 3.6 _+ 0.5 5.4 _+ 0.4* 3.7 _+ 0.4 
MAP (mm Hg) 72 _+ 4 71 ± 4 70 _+ 5 70 _+ 5 71 ± 5 
SVR (dynes/sec/cm 5) 1400 _+ 40 1395 _+ 50 1333 ± 40 890 _+ 40* 1340 _+ 40 
PVR/SVR ratio 0.44 ± 0.04 0,48 _+ 0.06 0.47 _+ 0.06 0.3 + 0.04* 0.44 _+ 0.04 
Values are mean plus or minus the standard error of the mean. Venous, Mixed venous; CVP, central venous pressure; LAP, left atrial pressure; MAP, mean 
arterial pressure; MPAP, mean pulmonary artery pressure; TPG, transpulmonary gradient; SVR, systemic vascular resistance. 
*p = 0.04 versus "Before" and "After" values. 
patients could be studied: patients undergoing valve 
replacement. Control of many variables that affect 
PVR was available in this group of patients. Surgical 
access allowed accurate measurement of pulmonary 
venous outflow pressure (left atrial pressure) for 
calculation of PVR. 7 The patient who was anes- 
thetized and receiving mechanical ventilation al- 
lowed for maintenance of a constant rate of 
ventilation and tidal volume to avoid mechanical 
alterations of PVR. s Furthermore, arterial P02 
could be well controlled and changes in acid-base 
status avoided. 6'9 
In our protocol, a standard cardiac anesthetic 
technique was used. Intravenous anesthetic agents 
were administered only before cardiopulmonary by-
pass and inhalational anesthetic agents were not 
administered after cessation of cardiopulmonary 
bypass until after the period of data collection. 
Therefore any influence of anesthesia on PVR was 
assumed to have been held constant during the 
period of data collection. Although the anesthetic 
technique may or may not influence the response of 
the pulmonary vasculature toinhaled NO, the influ- 
ence was held constant during the period of data 
collection. In addition, to optimize clinical relevance 
patients were examined early after operation. 
The present study was designed to examine the 
acute effects of inhaled NO administration. There- 
fore one may not draw conclusions regarding the 
effects of prolonged exposure. NO is a potentially 
toxic gas: inhalation of greater than 1000 ppm has 
been shown to cause acute lung injury in laboratory 
animals, a° In human beings, NO is believed to cause 
silo filler's disease. 11 Therefore prolonged adminis- 
tration of inhaled NO requires chemoluminescence 
monitoring to accurately measure the concentration 
of inhaled NO and to measure the exhaled concen- 
tration of its toxic metabolite, nitrogen dioxide 
(NO2). Blood samples are also required to measure 
the level of methemoglobin concentration. 2 During 
the brief administration of inhaled NO in the 
present study, there were no changes in level of NO2 
or methemoglobin. Despite these potential toxici- 
ties, prolonged administration of inhaled NO to 
patients with adult respiratory distress yndrome in 
concentrations upto 80 ppm and for durations up to 
53 days have not been found to produce lung 
toxicity. 12 Nonetheless, a trial of inhaled NO has 
been reported to precipitate pulmonary edema in a 
patient with stable heart failure. 13 Of particular 
concern in patients undergoing cardiac operations i  
the possibility that inhaled NO may depress myocar- 
dial contractility. Although no changes in cardiac 
output were found with inhaled NO in the present 
study, further investigation is required to determine 
the influence of inhaled NO on cardiac function. 
Pulmonary vascular tone is assumed to be closely 
related to intracellular levels of pulmonary vascular 
smooth muscle cGMP. Because phosphodiesterase 
activity determines the catabolic rate of cGMP, 
other investigators have targeted phosphodiesterase 
inhibition as a therapeutic strategy by which to lower 
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Fig. 1. The combination of inhaled NO plus dipyridam- 
ole produced a significant reduction in mean pulmonary 
arterial pressure without change in mean systemic arterial 
pressure. Values are mean plus or minus standard error of 
the mean. *p = 0.03 versus "Before" and "After" values. 
pulmonary vascular tone. 14' 15 In the present study, 
dipyridamole was used to inhibit phosphodiesterase 
activity; no hemodynamic effects were observed 
after administration of dipyridamole alone. In the 
present study, only the combination of increased 
cGMP production (inhaled NO) and inhibition of 
cGMP breakdown (dipyridamole) produced a 
marked reduction in PVR and pulmonary arterial 
pressure. The results of the present study may 
reflect he fact that patients were studied very early 
after cardiopulmonary bypass. However, we have 
previously reported that patients undergoing aorto- 
coronary bypass did respond to inhaled NO imme- 
diately after cardiopulmonary bypass, 3 which sug- 
gests a significance in the response to inhaled NO 
among patients with pulmonary hypertension 
caused by valvular heart disease. 
In mammalian tissues, at least seven isoforms of 
phosphodiesterase have been identified. Phospho- 
diesterase type V is specific for the breakdown of 
cGMP. 16 Although dipyridamole is a clinically avail- 
able, potent inhibitor of phosphodiesterase type V, 
its actions are somewhat nonspecific. For example, 
dipyridamote inhibits isoforms of phosphodiesterase 
other than type V. The possibility therefore xists 
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Fig. 2. The combination of inhaled NO plus dipyridam- 
ole produced a significant reduction in PVR and an 
associated significant increase in cardiac output. Values 
are mean plus or minus standard error of the mean. *p = 
0.02 versus "Before" and "After" values. 
that some of the hemodynamic changes noted in the 
present study were attributable to inhibition of 
isoforms of phosphodiesterase involved in adeno- 
sine 3',5'-cyclic adenosine monophosphate metabo- 
lism; 3',5'-cyclic adenosine monophosphate-medi- 
ated pathways are also important in the control of 
pulmonary vascular smooth muscle toneJ 7' 18 In 
addition, dipyridamole prevents adenosine reuptake 
by endothelial and red blood cells, 19 thereby poten- 
tiating the local actions of adenosine. Because aden- 
osine has been shown to produce selective pulmo- 
nary vasodilation in patients undergoing cardiac 
operation,20, 21one may not exclude some contribu- 
tion of adenosine to the hemodynamic effects noted 
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in the present study. Nonetheless, the results of the 
present study demonstrated hemodynamic effects 
only when the combination of inhaled NO and 
dipyridamole was used. 
In summary, the combination of dipyridamole 
and inhaled NO was effective in producing pulmo- 
nary vasorelaxation in patients undergoing cardiac 
operations in whom inhaled NO alone was ineffec- 
tive in lowering pulmonary arterial pressure and 
PVR. We conclude that such a two-pronged strategy 
of stimulating cGMP production (inhaled NO) and 
preventing its breakdown (dipyridamole) may offer 
effective control of refractory pulmonary hyperten- 
sion in patients undergoing cardiac operations. 
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Discussion 
Dr. R. Scott Mitchell (Stanford, Calif.). Dr. Fullerton 
has presented the results of a beautiful study demonstrat- 
ing a relatively selective effect on secondary pulmonary 
hypertension with augmentation of the supply of cGMP, a 
very potent smooth muscle relaxant, by administration of 
inhaled NO and simultaneous inhibition of its degrada~ 
tion. This group has been able to produce a relatively 
selective effect on the pulmonary vasculature. Although 
there were some lesser effects on the systemic vascular 
resistance, these were more than compensated for by 
increased cardiac output. The investigation is a straight- 
forward yet elegant one with each patient serving as his or 
her own control. One caveat is that this is not really severe 
pulmonary hypertension with mean pulmonary artery 
pressures averaging only about 38 or 39 mm Hg and the 
pulmonary hypertension was termed refractory only be- 
cause it failed to respond initially to inhaled NO. That 
leads to my first question. Do the authors think that this 
failure to respond to inhaled NO alone had any relation- 
ship to the altitude in Denver and the known pulmonary 
hypertensive effect of chronic hypoxia? 
Dr. Fullerton. That is a good question, and I do not 
know the answer. Among patients who are ambulatory 
and breathing room air in Denver, the normal mean 
pulmonary arterial blood pressure has been studied in the 
catheterization laboratory at the University of Colorado 
and it is 22 mm Hg, a little bit higher than it is at sea level. 
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The patients who undergo study in a protocol such as this 
are, of course, receiving mechanical ventilation and the 
inspired oxygen fraction among these patients is substan- 
tially higher than it is on room air. In most of the patients 
the inspired oxygen fraction approaches 90%. So, ac- 
knowledging that the barometric pressure in this sort of 
thing is different, I suspect hat altitude probably plays 
little role. It may, however, play a role in the condition of 
the pulmonary circulation in these patients before they 
undergo peration. It is clear, particularly in the pediatric 
population, that patients who live at elevations even 
higher than Denver, between 6000 and 9000 feet, will have 
severe pulmonary hypertension that is particularly difficult 
to control in the perioperative period. It may be variable. 
This problem is one that is difficult to study, however. 
Dr. Mitchell We have not used inhaled NO as the first 
line of therapy for pulmonary hypertension, and I would 
like to hear how these patients fared later in the operative 
course as regards conventional therapy, such as infused 
nitroglycerin or sodium nitroprusside. 
Dr. Fullerton. To be eligible for the study these patients 
could not require inotropic support or require other 
vasoactive agents, so this is a group of patients with 
significant pulmonary hypertension, yet in whom it seems 
to be compensated for from a hemodynamic standpoint. 
We do not believe it would be appropriate to study other 
patients. These patients all left the hospital with pulmo- 
nary arterial pressures that were approximately a mean of 
40 mm Hg, which is about twice the normal value for the 
local control group. 
Dr. Mitchell. Last, although such patients were obviously 
not included in this study, do you have any information for us 
as to patients in whom weaning from cardiopulmonary 
bypass failed, who have pulmonary hypertension and right 
ventricular failure? Have you tried this combination of 
dipyridamole and NO for those patients? 
Dr. Fullerton. We have, and I think it is fair to say the 
results are anecdotal. In that sort of situation there are so 
many variables that have an impact on the data that I 
believe it is difficult to conclude whether the treatment 
works under those circumstances. I will say that we have a 
similar protocol in which we use this combination in 
patients with adult respiratory distress yndrome, and the 
results are quite different. I think that the patients in 
whom weaning from cardiopulmonary bypass fails are 
somewhat similar to those in the adult respiratory distress 
syndrome group in the sense that protracted cardiopul- 
monary bypass induces ignificant lung injury. Something 
about the injured lung causes its response to be different, 
and in those situations we think our combined therapy has 
worked a couple of times. Why it has or has not is hard to 
know; 
Dr. Edwardl D. Verrier (Seattle, Wash.). I have two brief 
questions. The more common scenario, at least in our 
practice, is not the one in which a patient with a mean 
pressure of 40 mm Hg can be weaned from cardiopulmo- 
nary bypass without receiving some inotropes and the 
combination of a phosphodiesterase inhibitor as an ino- 
trope. Could you comment once again as to whether there 
is going to be some efficacy in that? 
The second, related question is that inhaled NO to date 
is not widely available. It is still on protocol. When we 
need it, we have to go to the neonatal intensive care unit 
and beg the neonatologist to borrow some. What is the 
status of inhaled NO for general use in its relationship to 
the Food and Drug Administration? 
Dr. Fullerton. In regard to your first question, faced 
with the situation that you described, and if you desire to 
use phosphodiesterase inhibition, it probably makes more 
sense to use an agent like milrinone. In that situation, the 
augmented contractility that would be offered is probably 
needed, and it may or may not be synergistic in that 
situation, but my advice would be not to use dipyridamole 
but instead to use milrinone. I would caution you, how- 
ever, that milrinone has been studied by our group in the 
laboratory, but other groups have demonstrated in human 
beings that the actions of milrinone seem to be more 
pronounced in the systemic irculation. All of us who have 
used milrinone have more than once seen an example of 
that: as soon as the drug administration starts there is a 
significant drop in blood pressure because the systemic 
circulation opens up more than the pulmonary circulation, 
which in that setting may be the rate-limiting step, and 
flow and cardiac output are unable to compensate and 
maintain blood pressure. Nonetheless, that would be my 
recommendation. 
I can tell you that our results in patients with adult 
respiratory distress syndrome with use of this sort of a 
protocol to modulate PVR have suggested that it will not 
work in patients with adult respiratory distress yndromes so 
there is something different about this group of patients as 
opposed to the adult respiratory distress yndrome group. 
NO is considered an experimental gent by the Food 
and Drug Administration. The distribution varies by ge- 
ography, but there are probably 100 centers across the 
country that have it available to them. To use it you must 
have an inyestigational new drug number from the Food 
and Drug Administration, which can be obtained. Call the 
Food and Drug Administration and ask how you get one. 
The real up-front cost associated with using it is about 
$40,000. You must have a chemiluminescence monitor, so a 
lot of places that have called us inquiring about how to 
prepare to use NO have been held up by this capital 
investment. If and when it will be used liberally is unknown. 
Dr. Joseph Bavaria (Philadelphia, Pa.). We have been 
using NO quite a bit recently and are initiating prospective 
studies. I do not think there is any way our institution 
could be blinded to its use because the NO canisters are so 
huge. 
I would like to ask the authors about the application of 
this in lung transplantation. Recently, we have been trying 
to operate on our patients with primary pulmonary hyper- 
tension without using bypass if possible, and we have been 
successful with Use of a combination of prostaglandin E 1 
and inhaled NO. We have not used the authors' two- 
pronged strategy, which I find intriguing. I would like your 
comments about the use of this drug in standard lung 
transplantation, as well as in something more experimen- 
tal such as I just mentioned. 
Dr. Fullerton. Parallel to the study that was presented 
by Dr. Bavaria at this meeting, several authors have 
presented ata to suggest that donation of the NO moiety 
during the period of reperfusion may well attenuate the 
lung injury that is inherent in lung transplantation. We 
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have not used that strategy clinically, and we have not 
needed to. When a lung transplantation goes sour it goes 
sour very quickly and very notably. ! believe that we have 
used NO in one or two of our lung transplant recipients, 
and in one of them it was clearly life saving. That was a 
patient who had severe lung injury, and most of the time 
we do not use that. 
We have been routinely using cardiopulmonary b pass 
for the pulmonary hypertensive group, so I cannot com- 
ment on your other question. 
Dr. Gregory Misbach (Redlands, Calif.). There may be 
some who already use dipyridamole in the preoperative 
period for its antiplatelet ffect. Can you give us any com- 
parison of oral and intravenous dosages and time courses 
such that by changing the preoperative dosage there might 
be some benefit in the ways that you have described? 
Dr. Fullerton. That is an interesting strategy. I would 
caution you about the use of the oral dose and comparing 
the oral dose with the intravenous dose. Early on we learned 
that if this drug is administered too rapidly, it will cause 
hypotension. The hypotension is transient, but it is some- 
thing that should be avoided. In our protocol we spend 
approximately 12 to 14 minutes infusing the dose Of dipyrid- 
amole. Wondering whether, if a little was good, a lot would 
be better, on occasion we have given up to 0.6 mg/kg and we 
have found that this routinely produces hypotension. In 
patients who are receiving dipyridamole preoperatively I 
really do not know how that might relate. It is an interesting 
thought, but I really cannot comment on that. 
Dr. Richard G. Fosburg (De Mar, Calif.). I would like to 
bring up a historical note for some of the membership. Dr. 
Fullerton was the 1990 Samson resident prize winner and 
serves as an example for the candidates for the 1996 
resident prize. He is also a credible component of our 
program. 
Appendix 
Hemodynamic formulas used are as follows: 
1. PVR (dynes • sec • cm s) = 
Mean pulmonary artery pressure - left atrial pressure 
× 80 
Cardiac output 
2. Systemic vascular esistance (dynes • sec • cm 5) = 
Mean arterial pressure - Central venous pressure 
× 8O 
Cardiac output 
3. Transpulmonary gradient (mm Hg) = 
(Mean pulmonary arterial pressure) - (Left atrial pressure) 
